Anti-HMGB1 treatment partially reversed the decrease in AQP4 levels, suggesting its potential role in mitigating brain edema, but did not significantly affect the reduction in PAR-1 levels (Figure 4A,B). The gene discussed is F2R; the disease is brain edema.